BayCurrent, Inc. Logo

BayCurrent, Inc.

Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.

6532 | T

Overview

Corporate Details

ISIN(s):
JP3835250006
LEI:
Country:
Japan
Address:
港区麻布台一丁目3番1号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BayCurrent, Inc. is a comprehensive consulting firm that provides a wide range of services to address complex management and strategic challenges. The firm specializes in areas including corporate strategy, digital transformation, AI adoption, business process optimization, and sustainability (GX). It partners with leading corporations and government agencies across diverse industries, such as automotive, telecommunications, and finance, to implement solutions that drive sustainable growth and create lasting value. BayCurrent supports clients from strategy formulation through to execution, aiming to contribute to their long-term development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 08:30
Interim Report
確認書
Japanese 8.8 KB
2025-10-15 08:30
Interim Report
半期報告書-第12期(2025/03/01-2026/02/28)
Japanese 234.4 KB
2025-07-03 08:30
Share Issue/Capital Change
訂正臨時報告書
Japanese 42.6 KB
2025-06-18 09:00
Share Issue/Capital Change
臨時報告書
Japanese 30.8 KB
2025-06-13 08:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-05-29 08:00
Post-Annual General Meeting Information
臨時報告書
Japanese 25.2 KB
2025-05-28 08:01
Registration Form
確認書
Japanese 8.8 KB
2025-05-28 08:00
Governance Information
内部統制報告書-第11期(2024/03/01-2025/02/28)
Japanese 23.1 KB
2025-05-28 08:00
Registration Form
有価証券報告書-第11期(2024/03/01-2025/02/28)
Japanese 968.4 KB
2025-05-13 08:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2024-10-10 08:05
Interim Report
半期報告書-第11期(2024/03/01-2025/02/28)
Japanese 300.9 KB
2024-10-10 08:05
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-07-11 08:05
Quarterly Report
四半期報告書-第11期第1四半期(2024/03/01-2024/05/31)
Japanese 248.9 KB
2024-07-11 08:05
Registration Form
確認書
Japanese 8.3 KB
2024-06-19 08:10
Share Issue/Capital Change
臨時報告書
Japanese 29.4 KB

Automate Your Workflow. Get a real-time feed of all BayCurrent, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BayCurrent, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BayCurrent, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan
4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.